Xcede Technologies announced that it has signed three collaboration agreements with Cook Biotech of West Lafayette, including a Development Agreement, a License Agreement and a Supply Agreement to complete development, seek regulatory clearance and produce Xcede's resorbable hemostatic patch.

Xcede Technologies, a subsidiary of Dynasil Corporation of America ("DCA"), is based in Rochester, MN and Seattle, WA and began operations in October 2013 following a technology transfer from Dynasil Biomedical, a subsidiary of DCA.

Xcede is committed to the development and manufacturing of innovative hemostatic and sealant products to control severe bleeding in surgical applications.

Xcede’s resorbable hemostatic patch is currently under development and the Company is anticipating starting clinical trials in early 2017.

"We are excited to announce this collaboration with Cook Biotech," said Linda Zuckerman, Ph.D., President and CEO of Xcede Technologies., Inc.

"We believe that Cook’s experience and depth in the marketplace will provide a solid foundation for bringing our hemostatic patch into clinical development and on to regulatory approval and commercial sales."

Umesh Patel, Ph.D., Vice President & General Manager of Cook Biotech Inc., states, "Cook’s SIS matrix technology combined with Xcede’s adhesive technology provides an excellent foundation for Xcede’s first product and the basis for potential expansion to other products to be commercialized with Cook. We are excited to announce this collaboration with Xcede Technologies."